BioAffinity Initiates Clinical Validation for Early Lung Cancer Test

Jul 20, 2018

|

Premium

NEW YORK (360Dx) – BioAffinity Technologies has begun clinical validation of a test for the early detection of lung cancer that uses flow cytometry and detects porphyrin molecules in sputum samples.

The San Antonio-based firm anticipates that its CyPath Lung diagnostic assay will be available as a laboratory-developed test from a CLIA-certified laboratory early next year, and is in discussion with an undisclosed lab that wants to license the technology, its CEO Maria Zannes said in an interview.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

Featured White Papers

Delivering Precision Health: the Role of Molecular Diagnostics

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Jul

23

Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.

Jul

30

Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul

31

Featured Webinar

Considerations and Impact of Implementing Targeted NGS in Myeloid Malignancies

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

Menu